BVE Invests in Psilera, Inc, a Next-Generation Psychedelics Biotech Focused on Hard-to-Treat Neurological Disorders

Tampa, Fla., June 28, 2024 – Bonaventure Equity, LLC (BVE), a leading venture capital firm specializing in life sciences discoveries inspired by cannabinoids and psychedelic compounds, is thrilled to announce its latest investment in Psilera, Inc. (Psilera). This Tampa-based biotech company is at the forefront of developing non-psychoactive, psychedelic-inspired compounds called neuroplastogens for hard-to-treat neurological disorders.

Partnership with Psilera

“We are excited to partner with the Psilera team to unlock the potential of these next-generation psychedelics-inspired compounds for treating long-term neurogenerative diseases,” said Ross O’Brien, Founder & Managing Partner of Bonaventure Equity. “As our portfolio expands, we are more focused than ever on backing strong science and talented teams.”

Co-founders Chris Witowski, PhD, and Jackie von Salm, PhD, shared: “It is refreshing to meet an investment team focused on supporting our entrepreneurial journey and infusing expertise into pharmaceutical pathways for developing new drugs and technologies. We are thrilled to welcome them into our impact-driven investment group.”

Psilera is advancing a robust patent portfolio including three neuroplastogen drug candidates, and with this investment, will advance PSIL-006, the lead candidate for the treatment of frontotemporal dementia

About Bonaventure Equity, LLC

Bonaventure Equity, LLC (BVE), with roots in the former leadership of Johnson & Johnson’s Venture Capital group and strategic family offices, focuses on early-stage life sciences breakthroughs. The firm invests in seed and series A opportunities, particularly those involving neuromodulating small molecules. Through partnerships with premier research institutions, BVE’s portfolio is uniquely positioned to bring new treatments and therapies to millions of patients suffering from CNS-related conditions.

About Psilera Inc.

Psilera is a biopharmaceutical company developing groundbreaking therapeutics for hard-to-treat neurogenerative diseases by creating a new class of psychedelic medicines. Psilera’s lead asset, PSIL-006, is a non-hallucinogenic psilocybin-derivative for the treatment of frontotemporal dementia (FTD). With a deep commitment to scientific excellence and patient centricity, Psilera is transforming the lives of individuals affected by devastating neurodegenerative diseases. Welcome to the new era of mindful medicine. For more information visit

For more information about Bonaventure Equity and its investment in Psilera, please get in touch.

Media Contact

Stephanie Lewis
Investor Relations & Communications
Bonaventure Equity, LLC

Scroll to Top

Sign up form